Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis.

Ronal Yosua LimenRudyanto SedonoAdhrie SugiartoTimotius Ivan Hariyanto

Published in: Expert review of anti-infective therapy (2021)

This study propose that JAK-inhibitors perhaps provide advantageous effects on Covid-19 outcomes. JAK-inhibitors may be given during 1-2 weeks of disease to optimize its beneficial effects in halting the exaggerated immune response.

Keyphrases

coronavirus disease
immune response
sars cov
type diabetes
metabolic syndrome
tyrosine kinase
weight loss